NO20091945L - Myke kapsler omfattende palonosetronhydroklorid med forbedret stabilitet og biotilgjengelighet - Google Patents

Myke kapsler omfattende palonosetronhydroklorid med forbedret stabilitet og biotilgjengelighet

Info

Publication number
NO20091945L
NO20091945L NO20091945A NO20091945A NO20091945L NO 20091945 L NO20091945 L NO 20091945L NO 20091945 A NO20091945 A NO 20091945A NO 20091945 A NO20091945 A NO 20091945A NO 20091945 L NO20091945 L NO 20091945L
Authority
NO
Norway
Prior art keywords
bioavailability
improved stability
palonosetron hydrochloride
soft capsules
methods
Prior art date
Application number
NO20091945A
Other languages
English (en)
Other versions
NO342353B1 (no
Inventor
Daniele Bonadeo
Ricardo Braglia
Enrico Braglia
Giorgio Calderari
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091945(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of NO20091945L publication Critical patent/NO20091945L/no
Publication of NO342353B1 publication Critical patent/NO342353B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det tilveiebringes en fast, oral doseringsform av palonosetron hydroklorid, metoder for å anvende doseringformen for å behandle emesis, og metoder for å fremstille doseringsformene. Doseringsformene har forbedret stabilitet og biotilgjengelighet og foreligger fortrinnsvis i form av flytende, fylte kapsler.
NO20091945A 2006-10-24 2009-05-19 Myke kapsler omfattende palonosetron hydroklorid med forbedret stabilitet og biotilgjengelighet NO342353B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85434206P 2006-10-24 2006-10-24
PCT/EP2007/009098 WO2008049552A1 (en) 2006-10-24 2007-10-19 Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability

Publications (2)

Publication Number Publication Date
NO20091945L true NO20091945L (no) 2009-05-25
NO342353B1 NO342353B1 (no) 2018-05-07

Family

ID=38921772

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091945A NO342353B1 (no) 2006-10-24 2009-05-19 Myke kapsler omfattende palonosetron hydroklorid med forbedret stabilitet og biotilgjengelighet

Country Status (36)

Country Link
US (2) US20080152704A1 (no)
EP (1) EP1940366B9 (no)
JP (1) JP5144527B2 (no)
KR (1) KR101441459B1 (no)
CN (1) CN101573106B (no)
AR (1) AR063362A1 (no)
AT (1) ATE427742T1 (no)
AU (1) AU2007308378B2 (no)
BR (1) BRPI0718497B1 (no)
CA (1) CA2666512C (no)
CL (1) CL2007003055A1 (no)
CO (1) CO6160289A2 (no)
CR (1) CR10728A (no)
CY (1) CY1109914T1 (no)
DE (1) DE602007000856D1 (no)
DK (1) DK1940366T3 (no)
EA (1) EA016455B1 (no)
ES (1) ES2325339T3 (no)
GT (1) GT200900096A (no)
HK (1) HK1117769A1 (no)
HN (1) HN2009000785A (no)
HR (1) HRP20090341T1 (no)
IL (1) IL198225A (no)
ME (1) ME01949B (no)
MX (1) MX2009004461A (no)
NO (1) NO342353B1 (no)
NZ (1) NZ576237A (no)
PL (1) PL1940366T3 (no)
PT (1) PT1940366E (no)
RS (1) RS50842B (no)
SI (1) SI1940366T1 (no)
SV (1) SV2009003238A (no)
TW (1) TWI367212B (no)
UA (1) UA97653C2 (no)
WO (1) WO2008049552A1 (no)
ZA (1) ZA200902773B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200806496B (en) * 2006-01-27 2009-12-30 Eurand Inc Drug delivery systems comprising weakly basic drugs and organic acids
NZ570039A (en) * 2006-01-27 2011-07-29 Eurand Inc Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
WO2010077669A2 (en) 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102048705B (zh) * 2009-11-10 2012-07-18 齐鲁制药有限公司 盐酸帕洛诺司琼口腔崩解片制剂及其制备方法
EP2499137A1 (en) * 2009-11-13 2012-09-19 Helsinn Healthcare S.A. Palonosetron metabolites
ES2494015T3 (es) * 2009-11-18 2014-09-12 Helsinn Healthcare Sa Composiciones para tratar nauseas y vómitos de origen central
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
PL2744497T3 (pl) 2011-10-18 2016-10-31 Terapeutyczne połączenia netupitantu i palonosetronu
CN107137374B (zh) * 2012-06-02 2020-04-07 正大天晴药业集团股份有限公司 帕洛诺司琼的固体药物组合物
US20160287524A1 (en) * 2013-03-19 2016-10-06 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015099381A1 (ko) * 2013-12-23 2015-07-02 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
JP2019019067A (ja) * 2017-07-13 2019-02-07 ニプロ株式会社 液体製剤
CN111205283A (zh) * 2020-01-20 2020-05-29 广州九植医药科技有限公司 一种盐酸帕洛诺司琼有关物质b的合成方法
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1015251A (en) * 1963-03-12 1965-12-31 Glaxo Lab Ltd Aqueous pharmaceutical compositions in capsule form
US4182914A (en) * 1974-01-22 1980-01-08 Nippon Oil Company Limited Process for continuously producing diisopropyl ether
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
EP0200444B1 (en) * 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
IE68434B1 (en) * 1989-11-28 1996-06-12 Syntex Inc New tricyclic compounds
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2823118B1 (fr) * 2001-04-04 2004-03-19 Lavipharm Lab Inc Nouvelle composition filmogene a usage topique et son utilisation pour la delivrance d'agents actifs
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
WO2004045615A1 (en) * 2002-11-15 2004-06-03 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents

Also Published As

Publication number Publication date
EA016455B1 (ru) 2012-05-30
PL1940366T3 (pl) 2009-09-30
JP5144527B2 (ja) 2013-02-13
UA97653C2 (ru) 2012-03-12
AR063362A1 (es) 2009-01-21
CL2007003055A1 (es) 2008-03-24
IL198225A (en) 2013-03-24
ES2325339T3 (es) 2009-09-01
NO342353B1 (no) 2018-05-07
TW200827355A (en) 2008-07-01
NZ576237A (en) 2011-12-22
CN101573106A (zh) 2009-11-04
SV2009003238A (es) 2009-11-09
CA2666512A1 (en) 2008-05-02
EA200970396A1 (ru) 2009-10-30
ATE427742T1 (de) 2009-04-15
DK1940366T3 (da) 2009-06-29
KR20090073234A (ko) 2009-07-02
HN2009000785A (es) 2011-10-14
AU2007308378B2 (en) 2013-02-21
GT200900096A (es) 2011-08-29
MX2009004461A (es) 2009-09-16
ZA200902773B (en) 2010-03-31
HRP20090341T1 (en) 2009-07-31
JP2009507933A (ja) 2009-02-26
KR101441459B1 (ko) 2014-09-18
HK1117769A1 (en) 2009-01-23
WO2008049552A1 (en) 2008-05-02
CR10728A (es) 2009-07-23
TWI367212B (en) 2012-07-01
BRPI0718497B1 (pt) 2024-02-06
CO6160289A2 (es) 2010-05-20
EP1940366B1 (en) 2009-04-08
IL198225A0 (en) 2009-12-24
CN101573106B (zh) 2013-07-24
CY1109914T1 (el) 2014-09-10
EP1940366A1 (en) 2008-07-09
PT1940366E (pt) 2009-06-17
DE602007000856D1 (de) 2009-05-20
RS50842B (sr) 2010-08-31
EP1940366B9 (en) 2009-12-02
US20170035748A1 (en) 2017-02-09
AU2007308378A1 (en) 2008-05-02
US20080152704A1 (en) 2008-06-26
BRPI0718497A2 (pt) 2014-07-08
CA2666512C (en) 2014-05-27
ME01949B (me) 2010-08-31
SI1940366T1 (sl) 2009-08-31

Similar Documents

Publication Publication Date Title
NO20091945L (no) Myke kapsler omfattende palonosetronhydroklorid med forbedret stabilitet og biotilgjengelighet
NO2017036I1 (no) Daklatasvir og farmasøytisk akseptable salter derav, spesielt daklatasvir dihydroklorid
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
MY149731A (en) Compounds
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
EA201001334A1 (ru) Твёрдый препарат гидрохлорида карипразина для перорального введения
NO20073551L (no) Nikotinacetylkolinreseptorligander
NO20084826L (no) Ny administrasjonsform av racecadotril
PL2588090T3 (pl) Doustne farmaceutyczne postacie dawkowania zawierające eteksylan dabigatranu i jego farmaceutycznie dopuszczalne sole
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
WO2008156550A3 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
UA107334C2 (ru) Производные аминоэфиров алкалоидов и их лекарственные композиции
MX2010001574A (es) Ligandos del receptor cannabinoide.
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
DK2350026T3 (da) Sulfoximinsubstituerede anilinopyrimidinderativer som cdk-inhibitorer, fremstilling og anvendelse heraf som lægemiddel
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
DK2448561T3 (da) Faste farmaceutiske fast dosis-sammensætninger omfattende irbesartan og amlodipin, deres fremstilling og deres terapeutiske anvendelse
GEP20135859B (en) Stable combined pharmaceutical composition
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
DK2244703T3 (da) Lægemiddel og fremstillingen og anvendelse deraf i behandlingen af smertefulde neuropatier
EA200970816A1 (ru) Новая лекарственная форма